Heparin Sodium
HEPASTAR 5000i.u.
Features:
BRAND:
HEPASTAR 5000
GENERIC:
HEPARIN SODIUM
PREPARATION:
5000 IU/ML SOLUTION FOR INJECTION (IV. SC)
CLASSIFICATION:
ANTICOAGULANT
FORMULATION:
EACH ML CONTAINS:
HEPARIN SODIUM B.P ……5000 IU (DERIVED FROM MUCOSA)
INDICATION:
Heparin is used in the treatment and prophylaxis of venous thromboembolism (deep venin thrombosis and pulmonary embolism), especially prophylaxis in surgical patients and in those pregnant woman at particular risk. It is also used in the management of arterial thromboembolism including that associated with unstable angina pectoris, myocardial infarction, acute peripheral arterial occlusion, and stroke.
CONTRAINDICATION:
Known hypersensitivity to heparin, especially when severe heparin-induced thrombocytopenia has occurred in recent months. Haemorrhagic blood disorders-especially thrombocytopenia and haemophilia. Conditions where haemorrhage is a particular risk; Aneurysm ,cerebral or aortic ,Hypertension severe or uncontrolled, Threatened abortion, Recent childbirth, Subacute bacterial endocarditis, Pericarditis, Vasculitis, severe , Active cavitating tubercolsis
DOSAGE:
-For treatment of venous Thromboembolism
-5000 units(10000 units maybe required in severe pulmonary embolism) is followed by continuous intravenous infusion of 1000 to 2000 units/hour or subcutaneous injection of 15000 units every 12 hours.
-For Prophylaxis of postoperative venous Thromboembolism.
-Subcutaneous doses used are 5000 units 2 hours before surgery then every 8 to 12 hours for 7 days or until patient is ambulant.
-Unstable angina or acute peripheral arterial embolism
-May be given by continuous intravenousinfusion in the same doses as those recommended for the treatment of venous thromboembolism.
PHARMACOKINETCS:
Heparin inhibits the clotting of blood both vitro, and in vivo. The anticoagulant action of the heparin requires the presence of a plasma alpha-globulin, referred to as “heparin cofactor” a substance that appears to be identical with normal plasma antithrombin (antithrombin III). Heparin is well absorbed after intramuscular or subcutaneous injection. In the blood it is evenly distributed between white cells and plasma. The half lives of 100, 200 and 400 units/kg, injected intravenously, are 56,96, and 152 minutes respectively.
ADVERSE EFFECT:
Heparin can give rise to hemorrhage as consequence of its action. It can also cause thrombocytopenia either through a direct effect or through an immune effect producing a platelet-aggregating antibody. Hypersensitivity reactions may occur, as may local irritant effects, skin necrosis. Alopecia and osteoporosis resulting in spontaneous fractures have occurred after prolonged use of heparin.
AVAILABIITY:
5 ml USP Type I clear glass vial